Preliminary Results for December 2020

Number of samples tested from 1 - 31 December 2020: 151

⇒ We asked people what drug they were bringing to be tested.

Expected substance	n
Opioid Down: Fentanyl and/or Heroin	58
Stimulant: Cocaine HCl or Base, Methamphetamine	40
Psychedelic	16
Dissociative	12
Benzodiazepine	8
Other Opioid (pharmaceutical opioid, carfentanil)	3
Other Stimulant (Amphetamine)	1
Unknown/Missing	13

⇒ We tested each sample to determine what components were present. This included checking if the expected active was found, and any other notable components that may result in unexpected effects.

(-,-) no expected active, no other notable component	(-,+) no expected active, other notable component
(+,-) expected active, no other notable component	(+,+) expected active, other notable component

Expected substance		Notable components detected*	n
Opioid Down			58
	(-,+)	No expected active, other notable component	1
		MDMA	1
	(+,-)	Expected active, no other notable component	24
		Fentanyl or analogue	23
		Heroin	2

Data are preliminary. There were missing data for some samples. Instruments may not be able to detect all ingredients and certainty of interpretations may vary. Multiple substances may be present in one sample and substances may be present in trace concentrations. Expected substances were grouped so there may not be precise agreement between expected and detected active. *Notable components: Includes all expected actives as well as unexpected components of note, such as those with the potential for unexpected effects or that impact the effectiveness of naloxone.

Preliminary Results for December 2020

Expected substance		Notable components detected*	n
Opioid Down (cont.)	(+,+)	Expected active, other notable component	33
		Fentanyl or analogue	32
		Etizolam ¹	24
		Benzodiazepine (undifferentiated) ¹	8
		Heroin	4
		Carfentanil	2
		Cocaine Base	2
		Cocaine HCl	2
		6-Acetylmorphine	1
		Methamphetamine	1
Cocaine HCl or Base			29
	(+,-)	Expected active, no other notable component	28
		Cocaine HCl	27
		Cocaine Base	1
	(+,+)	Expected active, other notable component	1
		Cocaine Base	1
		Fentanyl or analogue	1
Methamphetamine			11
	()	No expected active, no other notable component ²	1
	(+,-)	Expected active, no other notable component	8
		Methamphetamine	8
	(+,+)	Expected active, other notable component	2
		Fentanyl or analogue	2
		Methamphetamine	2

Data are preliminary. There were missing data for some samples. Instruments may not be able to detect all ingredients and certainty of interpretations may vary. Multiple substances may be present in one sample and substances may be present in trace concentrations. Expected substances were grouped so there may not be precise agreement between expected and detected active. *Notable components: Includes all expected actives as well as unexpected components of note, such as those with the potential for unexpected effects or that impact the effectiveness of naloxone. ¹27 contained one or more benzodiazepine related component. ²May be due to limitations of technology to detect certain substances.

Preliminary Results for December 2020

Expected substance		Notable components detected*	n
Psychedelic			16
	(-,-)	No expected active, no other notable component ²	1
	(-,+)	No expected active, other notable component	2
		MDMA ³	1
		MDA^4	1
		Ketamine	1
	(+,-)	Expected active, no other notable component	13
		MDMA	11
		MDA	2
		LSD	1
Dissociative			12
	(-,+)	No expected active, other notable component	1
		Methamphetamine	1
	(+,-)	Expected active, no other notable component	11
		Ketamine	11
Benzodiazepine			8
	(+,-)	Expected active, no other notable component	8
		Flualprazolam	4
		Benzodiazepine (undifferentiated)	2
		Alprazolam	1
		Etizolam	1
Other Opioid			3
	(-,-)	No expected active, no other notable component ²	2
	(-,+)	No expected active, other notable component⁵	1
		Fentanyl or analogue	1
		Heroin	1

Data are preliminary. There were missing data for some samples. Instruments may not be able to detect all ingredients and certainty of interpretations may vary. Multiple substances may be present in one sample and substances may be present in trace concentrations. Expected substances were grouped so there may not be precise agreement between expected and detected active. *Notable components: Includes all expected actives as well as unexpected components of note, such as those with the potential for unexpected effects or that impact the effectiveness of naloxone. ²May be due to limitations of technology to detect certain substances. ³Expected to be 2CB. ⁴Expected to be MDMA. ⁵Expected to be carfentanil.

Preliminary Results for December 2020

Expected substance		Notable components detected*	n
Other Stimulant			1
	(-,+)	No expected active, other notable component	1
		Methamphetamine	1
Unknown/Missing ⁶			13
		Fentanyl or analogue	5
		Benzodiazepine (undifferentiated)	1
		Cephalexin	1
		Cocaine Base	1
		Cocaine HCl	1
		Dimenhydrinate	1
		Doxycycline	1
		Etizolam	1
		Heroin	1
		Phenacetin	1

Data are preliminary. There were missing data for some samples. Instruments may not be able to detect all ingredients and certainty of interpretations may vary. Multiple substances may be present in one sample and substances may be present in trace concentrations. ¹Expected substances were grouped so there may not be precise agreement between expected and detected active. *Notable components: Includes all expected actives as well as unexpected components of note, such as those with the potential for unexpected effects or that impact the effectiveness of naloxone. ⁶All notable components detected for these categories reported together.

Preliminary Results for December 2020

*Notable components: Includes all expected actives as well as unexpected components of note, such as those with the potential for unexpected effects or that impact the effectiveness of naloxone.

The Vancouver Island Drug Checking Project is based out of the University of Victoria and operates community-wide drug checking services within Victoria, BC. We are continuing to offer drug checking services in response to the dual public health emergencies, and exploring new ways to better reach those who may benefit from this service. We have now partnered with Vancouver Island University to improve detection and reporting. See our website for our blog and reports with additional analyses.

Our project respectfully acknowledges that we work as visitors on the traditional territory of the Lkwungen (Songhees), Wyomilth (Esquimalt), and WSÁNEĆ (Saanich) peoples of the Coast Salish Nation. We also acknowledge the inextricable links between research, colonization and racism against Indigenous peoples, which continue to this day. Ending the violence faced by people who use substances and the overdose crisis cannot be achieved without facing the legacy through which we have come to be in this territory.

For more information please visit: substance.uvic.ca

We gratefully acknowledge our partners and funders on this project

Our Partners

Agilent Technologies Compute Canada SOLID Outreach

AVI Health and Community Services IBM Canada STS Pharmacy

BC Ministry of Health

BC Ministry of Mental Health and Addictions Lantern Services Vancouver Island University

BC Support Vancouver Island Centre PerkinElmer Inc Westgrid

Our Funders

ProSpect Scientific

Health Canada Substance Use and Addictions Program

Natural Sciences and Engineering Research Council

Vancouver Foundation

Canadian Institutes of Health Research

Michael Smith Foundation for Health Research

Canadian Institute for Substance Use Research